The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection

Overview

Journal P T

Specialty Pharmacology

Date 2011 Jul 26

PMID 21785551

Authors

Jason J Schafer

Saranyu Ravi

Evelyn V Rowland

Germin Shenoda

Nicholas Leon

Affiliations

Soon will be listed here.

References

Sulkowski M, Thomas D, Mehta S, Chaisson R, Moore R . Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002; 35(1):182-9. DOI: 10.1053/jhep.2002.30319. View

Weiner M, Benator D, Peloquin C, Burman W, Vernon A, Engle M . Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin Infect Dis. 2005; 41(9):1343-9. DOI: 10.1086/496980. View

HSU H, Rydzak C, Cotich K, Wang B, Sax P, Losina E . Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med. 2010; 12(2):97-108. PMC: 3010302. DOI: 10.1111/j.1468-1293.2010.00856.x. View

Palumbo P, Lindsey J, Hughes M, Cotton M, Bobat R, Meyers T . Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010; 363(16):1510-20. PMC: 3021781. DOI: 10.1056/NEJMoa1000931. View

Guay L, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C . Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999; 354(9181):795-802. DOI: 10.1016/S0140-6736(99)80008-7. View

Wakeham K, Parkes-Ratanshi R, Watson V, Ggayi A, Khoo S, Lalloo D . Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. J Antimicrob Chemother. 2009; 65(2):316-9. PMC: 2809247. DOI: 10.1093/jac/dkp451. View

Hsiou Y, Ding J, Das K, Clark Jr A, Boyer P, Lewi P . The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol. 2001; 309(2):437-45. DOI: 10.1006/jmbi.2001.4648. View

Izurieta P, Kakuda T, Feys C, Witek J . Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women. HIV Med. 2011; 12(4):257-8. DOI: 10.1111/j.1468-1293.2010.00874.x. View

Arendt G, de Nocker D, von Giesen H, Nolting T . Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf. 2007; 6(2):147-54. DOI: 10.1517/14740338.6.2.147. View

10.

Pozniak A, Morales-Ramirez J, Katabira E, Steyn D, Lupo S, Santoscoy M . Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2009; 24(1):55-65. DOI: 10.1097/QAD.0b013e32833032ed. View

11.

Ji P, Damle B, Xie J, Unger S, Grasela D, Kaul S . Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. J Clin Pharmacol. 2008; 48(8):948-56. DOI: 10.1177/0091270008319792. View

12.

Cramer Y, Rosenkranz S, Hall S, Szczech L, Amorosa V, Gupta S . Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177. J Acquir Immune Defic Syndr. 2010; 54(4):e7-9. PMC: 2912759. DOI: 10.1097/QAI.0b013e3181e2d5e5. View

13.

Damle B, LaBadie R, Crownover P, Glue P . Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol. 2008; 65(4):523-30. PMC: 2291383. DOI: 10.1111/j.1365-2125.2007.03085.x. View

14.

Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L, Jochmans D . TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol. 2005; 79(20):12773-82. PMC: 1235844. DOI: 10.1128/JVI.79.20.12773-12782.2005. View

15.

Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga J, Molina J . Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009; 23(17):2289-300. DOI: 10.1097/QAD.0b013e3283316a5e. View

16.

Kakuda T, Scholler-Gyure M, Hoetelmans R . Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2010; 50(1):25-39. DOI: 10.2165/11534740-000000000-00000. View

17.

Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J . Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos. 1999; 27(8):895-901. View

18.

Liedtke M, Rathbun R . Warfarin-antiretroviral interactions. Ann Pharmacother. 2009; 43(2):322-8. DOI: 10.1345/aph.1L497. View

19.

Sriwiriyajan S, Mahatthanatrakul W, Ridtitid W, Jaruratanasirikul S . Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients. Eur J Clin Pharmacol. 2007; 63(5):479-83. DOI: 10.1007/s00228-007-0282-8. View

20.

Gerber J, Rosenkranz S, Fichtenbaum C, Vega J, Yang A, Alston B . Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr. 2005; 39(3):307-12. DOI: 10.1097/01.qai.0000167156.44980.33. View